Latest News

CSL invested over A$1.2 billion in R&D in financial year 2019 as the company progressed what it described as a "highly differentiated product portfolio mix".

Views are being sought on a discussion document designed to advance industry’s role in the future of genomics in Australian healthcare. This discussion document provides an early perspective on...

Griffith University’s Institute for Glycomics has partnered with Hong Kong-listed China Grand Pharma’s newly established Australian company Grand Medical to progress the development of a new drug for Human Parainfluenza Virus.

The federal government has announced it has granted Major Project Status for the medicinal cannabis industry for the development of new facilities in South East Queensland and regional Victoria.

SUDA Pharmaceuticals (ASX:SUD) has entered into a fully-funded, feasibility study and option agreement with Laboratorios Ordesa, a Spanish pharmaceutical company that focuses on nutrition, health and well-being.

Australian biotechnology company Opthea (ASX:OPT) has announced it has received commitments from sophisticated and institutional investors to raise $50 million via a private placement.

Australian company Noxopharm (ASX:NOX) has reported positive end-of-study data from its DARRT-1 Phase 1b trial of Veyonda.

Zelira Therapeutics, formerly known as Zelda Therapeutics (ASX:ZLD), has announced the completion of the 100 per cent acquisition of Ilera Therapeutics.

The industry and medical research community have the potential to deliver transformational change for patients based on the recent dramatic increase in human biology, according to Dr Paul Stoffels, Johnson & Johnson vice chairman and chief scientific officer.

Consumer Healthcare Products Australia, formerly ASMI, has announced the election and appointment of new directors to its Board.

New directors for ARCS Australia with the addition of former CEO Marisa Peterson and the founder and managing director of Commercial Eyes, Andrew Carter.

SUDA Pharmaceuticals (ASX:SUD), a company focused on oro-mucosal drug delivery, has announced the appointment of Dr Michael Baker as its CEO, commencing 2 January 2020.